本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、会议召开和出席情况 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 以公告方式向全体股东发出召开 2024 年度股东大会的通知。本次股东大会采取 现场投票和网络投票相结合的方式召开。其中现场会议于 2025 年 5 月 19 日下午 14:00 在中国（河北）自由贸易试验区正定片区正定县高新技术产业开发区南区 梦龙街 71 号河北常山生化药业股份有限公司办公楼会议室召开，本次会议由董 事会召集，董事长高晓东先生主持本次会议；通过深圳证券交易所交易系统进行 网络投票的具体时间为2025年5月19日9:15—9:25、9:30—11:30、13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为 2025 年 5 月 19 日 9:15 至 15:00 期间的任意时间。 出席本次股东大会的股东共604名，代表有表决权股份共计304,838,808股， 占公司有表决权股份总数的 33.1685％。其中：参加现场会议的股东共 9 名，代 表有表决权股份 283,313, ...

证券代码：300255 证券简称：常山药业 公告编号：2025-21 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"）于 2024 年 5 月 20 日 召开的 2023 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公 司为全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"）融资 提供不超过 42,000 万元的连带责任保证额度。上述额度期限自股东大会审议通 过之日起至 2024 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关 于提供担保额度预计的公告》（公告编号：2024-22）。 二、担保进展 2025 年 5 月 15 日，公司与中国农业银行股份有限公司正定县支行（以下简 称"农业银行"）签订了《保证合同》，公司为凯库得与农业银行签订的固定资 产借款合同下 536.13 万元的本金及利息提供连带责任保证。 3．注册地址：中国（河北）自由贸易试验区正定片区正定县高新技术产业 开发区北区赵普大街 ...

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [6] Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11] - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13] - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 industry indices [2][11] - The year-to-date performance shows a 1.19% increase, ranking 15th among the indices [13] 2. Key Company Announcements - Notable companies such as Kellytai, BGI Genomics, and Dongfang Bio have reported varying financial results, with some showing declines in net profit [21] 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22] - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22] - The report suggests that the innovative drug sector is entering a phase of realization of results, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22] 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%) and Haichuang Pharmaceutical (+25.85%), while the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20]

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [6]. Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11]. - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13]. - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16]. Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 sectors [2][11]. - The year-to-date performance shows a 1.19% increase, ranking 15th among the sectors [13]. 2. Key Company Announcements - Key companies such as Kelly Tai, BGI Genomics, and Dongfang Bio reported varying financial results, with some showing significant declines in net profit [21]. 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22]. - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22]. - The report suggests that the innovative drug sector is entering a phase of realization, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22]. 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%), Haichuang Pharmaceutical (+25.85%), and Jinhao Medical (+25.32%) [3][20]. - Conversely, the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20].

证券代码：300255 证券简称：常山药业 公告编号：2025-20 河北常山生化药业股份有限公司 关于提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"、"母公司"）于 2024 年 5 月 20 日召开的 2023 年度股东大会审议并通过《关于提供担保额度预计的议 案》、于 2024 年 9 月 18 日召开的 2024 年第一次临时股东大会审议并通过《关于 提高提供担保额度的议案》，同意全资子公司常山生化药业（江苏）有限公司（以 下简称"江苏子公司"）为母公司借款融资提供不超过 11.2 亿元的担保额度，同 意公司为全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"） 融资提供不超过 4.2 亿元的连带责任保证额度。上述额度期限自股东大会审议通 过之日起至 2024 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关 于提供担保额度预计的公告》（公告编号：2024-22）及《关于提高提供担保额 度的公告》（公告编号：2024-38）。 1．企业名称：河北常山 ...

每经记者｜许立波 每经编辑｜文多 丨 2025年5月8日 星期四 丨 5月7日上午，常山药业盘中一度涨停，股价创历史新高。7日上午，《每日经济新闻》记者致电公司证 券部，对方表示公司生产经营一切正常。同日晚间，常山药业公告称，公司艾本那肽注射液尚未上市销 售，该注射液用于治疗2型糖尿病的上市许可申请已经获得国家药监局受理，目前处于专业审评阶段， 艾本那肽最终能否获批上市及获批时间仍存在不确定性。即使未来艾本那肽上市，也面临较高的市场竞 争风险。 点评：公司公告已明确，核心产品艾本那肽尚处于审评阶段，且未来面临较高竞争压力和不确定性。短 期内，公司股价已明显脱离基本面，存在情绪炒作迹象。 NO.1 将减肥药纳入基本药物目录？世卫组织回应 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自 担。 5月7日，昊海生科公告称，公司收到控股股东、实际控制人之一蒋伟通知，其于近日收到中国证监会出 具的《立案告知书》：因涉嫌内幕交易，决定对其立案。据昊海生科了解，该事项与公司股票无关。本 次事项系对蒋伟个人的调查，其不参与公司日常经营管理，该事项不会对公司日常经营活动产生重大影 响。 点评：尽 ...

Macro News - The People's Bank of China announced a reduction in the reserve requirement ratio by 0.5 percentage points and a decrease in policy interest rates by 0.1 percentage points, along with adjustments to structural monetary policy tools [3] - The National Financial Regulatory Administration plans to enhance the role of insurance funds as patient and long-term capital, introducing measures to support capital market stability and activity [3] - The China Securities Regulatory Commission (CSRC) is set to implement reforms for the Sci-Tech Innovation Board and the Growth Enterprise Market, and will revise the management measures for major asset restructuring of listed companies [3] Industry News - China's gold reserves reached 73.77 million ounces at the end of April, marking an increase of 70,000 ounces and continuing a six-month trend of gold accumulation [6] - The CSRC has issued an action plan to promote the high-quality development of public funds, which includes adjusting management fees and establishing a performance-based assessment system for fund managers [6] - Shanghai announced a reduction in personal housing provident fund loan rates, effective from May 8, 2025, with rates for first-time homebuyers set at 2.1% for loans under five years and 2.6% for loans over five years [6] Company News - Geely Automobile announced a proposal to privatize Zeekr at a price of $2.57 per share [9] - Kweichow Moutai reported a share buyback of 934,800 shares in April, with a total expenditure of 1.44 billion yuan [10] - BeiGene reported a net loss of 94.5 million yuan in the first quarter [10] - Qingdao Beer plans to acquire 100% equity of Jimo Huangjiu [10] - Hive Storage confirmed that its LPDDR4X and eMMC storage products are being used in the Go2 intelligent robotic dog developed by Yushu Technology [10]

Group 1 - Geely Auto proposed to privatize Zeekr with an offer of $2.57 per share, representing a 13.6% premium over the last trading price [1] - The offer also includes a premium of 20.0% over the volume-weighted average price of the last 30 trading days [1] - Geely currently holds approximately 65.7% of Zeekr's issued share capital [1] Group 2 - Sun Group announced the U.S. Department of Commerce has revoked its investigation into steel wheels made in Vietnam using Chinese components [2] - The revocation is expected to positively impact the company's export orders and future overseas business layout [2] Group 3 - Qingdao Beer plans to acquire 100% equity of Jimo Yellow Wine for a total consideration of RMB 665 million [3] - The acquisition aims to enhance industry synergy, competitiveness, and expand product lines and market channels [3] Group 4 - BeiGene reported a net loss of 94.503 million yuan in Q1 2025, a reduction in loss compared to the previous year [4] - The company achieved total revenue of 8.048 billion yuan, a year-on-year increase of 50.2%, driven by sales growth of its self-developed products [4] Group 5 - Daqin Railway reported a 0.99% year-on-year increase in cargo transportation volume for April [5] - Shaanxi Coal's self-produced coal sales reached 13.1033 million tons in April, up 0.76% year-on-year [5] Group 6 - Shennong Group sold 227,300 pigs in April, marking a 32.85% year-on-year increase [6] - Poly Developments reported a 25.44% year-on-year decrease in contracted sales amounting to 24.622 billion yuan in April [6] Group 7 - Hainan Development plans to acquire 51% equity of Wangying Technology [7] - Huafeng Measurement Control's shareholders plan to transfer 2.9% of shares at an initial price of 121.42 yuan per share [7] Group 8 - Various companies reported significant stock price fluctuations, with Changshan Pharmaceutical's injection not yet on the market and facing regulatory uncertainties [8] - The company is in the professional review stage for its diabetes treatment application [8]

Market Performance - On May 7, the Shanghai Composite Index rose by 0.80%, with institutional investors appearing on the trading lists of 18 stocks, net buying 6 and net selling 12 [1] - The average increase of stocks with net institutional purchases was 8.24%, outperforming the Shanghai Composite Index [3] Institutional Buying and Selling - The stock with the highest net institutional purchase was Tianyuan Dike, which closed up 8.46% with a turnover rate of 48.90%, and a total transaction amount of 4.747 billion [2] - Changshan Pharmaceutical hit the daily limit with a closing increase of 20.00% and a turnover rate of 10.63%, with net institutional purchases of 5129.86 million [2] - The stock with the highest net institutional sale was Hezhu Intelligent, with a net selling amount of 6897.78 million [3][6] Stock Flow and Performance - The stocks with significant net inflows included Tianyuan Dike and Changshan Pharmaceutical, while stocks like Hezhu Intelligent and Nanfang Precision experienced notable net outflows [3][4] - Among the stocks with institutional net purchases, only one stock provided a half-year performance forecast, with a projected net profit increase of 4.72% for Zhongjie Automobile [3] Deep and Hong Kong Stock Connect - On May 7, 12 stocks on the trading list had appearances from the Deep and Hong Kong Stock Connect, with net purchases in stocks like Zongshen Power and Tianyuan Dike [7][8] - The net purchase amounts for these stocks included 5462.66 million for Zongshen Power and 4493.94 million for Tianyuan Dike [8]